Physician profile
Anusha Ramadhas
NPI 1932506599
$1,840.52
in general payments reported to CMS, 2019-2025
18 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $22.65 · 2021: $66.98 · 2022: $178 · 2023: $680 · 2024: $584 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,372.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $248.02 | 2023-2024 | Evenity |
| Abbott Laboratories | $246.51 | 2021-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $202.30 | 2019-2023 | |
| Medtronic, INC. | $182.52 | 2023-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Dexcom, INC. | $141.84 | 2022-2024 | Dexcom G6 Transmitter |
| Beta Bionics, INC. | $140.63 | 2023 | Ilet Bionic Pancreas |
| Bayer Healthcare Pharmaceuticals INC. | $121.84 | 2024 | |
| Insulet Corporation | $109.71 | 2023 | Omnipod |
| Astellas Pharma US INC | $98.91 | 2024 | Veozah |
| Lilly USA, LLC | $65.68 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $61.85 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $60.81 | 2024 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $52.20 | 2019 | |
| Tandem Diabetes Care, INC. | $28.90 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Cequr Corporation | $23.00 | 2025 | Cequr Simplicity |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $22.53 | 2024 | |
| Sequel Med Tech, LLC | $17.62 | 2025 | Twiist |
| Shire North American Group INC | $15.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anusha Ramadhas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.